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Background Danon disease is a rare X-linked multisystemic disorder that has primarily been described in male patients.
...................................................................................................................................................................................................
Case summary We present three female patients with Danon disease with a predominantly cardiac phenotype in whom disease
onset and expression was very different from that of male patients. Case 1 was first admitted for acute heart failure
and then readmitted a few months later for cardiac shock, necessitating mechanical support, and heart transplant-
ation. Case 2 had complex arrhythmias for which many antiarrhythmic drugs were tried with only limited success.
Her disease accelerated after her first pregnancy, and she showed reduced left ventricular function and dilated car-
diomyopathy. Case 3 was referred for near syncope and ablated for an accessory pathway; she had extensive left
ventricular hypertrophy. In all three cases, a final diagnosis of Danon disease was only made after genetic testing
that identified a causal variant in the lysosome-associated membrane protein 2 gene.
...................................................................................................................................................................................................
Discussion Danon disease in female patients is a challenging diagnosis that may not be identified until genetic testing has been
performed.
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Learning points
• Danon disease is a rare disease. The primarily cardiac phenotype seen in our three female cases is even rarer.
• The presentation of Danon disease in women can be more variable than that typically seen in men.
• Danon disease should be considered in female patients with either heart failure or arrhythmias without a clear diagnosis and/or with a pre-
excitation-like electrocardiogram. Genetic testing plays a crucial role in this diagnosis.
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Danon disease is a rare X-linked multisystemic disorder that has pri-
marily been described in males.1 It was first described as a lysosomal
glycogen storage disease characterized by proximal myopathy, men-
tal retardation, and hypertrophic cardiomyopathy.2 The gene defect
underlying Danon disease causes a deficiency of lysosome-associated
membrane protein 2 (LAMP2).3 In Danon disease, typical cardiac
presentation occurs during adolescence and includes left ventricular
hypertrophy (LVH) and a Wolff–Parkinson–White pre-excitation
pattern on the electrocardiogram (ECG).1 Here, we report three in-





Case 1 was admitted to the hospital with acute heart failure at the
age of 20 years. She had no medical history aside from an episode of a
common cold 2 months earlier. Her ECG (Figure 1A) showed sinus
tachycardia, a short PR interval without pre-excitation and
broadened and fractioned QRS complexes with inferolateral repola-
rization abnormalities. Echocardiographic evaluation showed a
hypertrophic dilated left ventricle with poor function and signs sug-
gestive of non-compaction cardiomyopathy. Cardiovascular magnetic
resonance imaging did not confirm the presence of non-compaction
cardiomyopathy (Figure 2). Coronary angiography was normal, and
subsequent myocardial biopsy revealed no signs suggestive of a stor-
age disease or myocarditis. The patient received standard heart fail-
ure treatment and an implantable cardioverter-defibrillator. A few
months later, she presented at the emergency department with in-
tractable cardiac shock. Mechanical extracorporeal biventricular sup-
port was initiated, and the patient underwent heart transplantation 3
weeks later. In the years, thereafter, she remained clinically stable.
Genetic testing was performed 5 years later, and a mutation was
found in LAMP-2 (c.557-1G>C (NM_002294.2)). The explanted
heart was re-examined in 2016 and again showed signs of biventricu-
lar hypertrophy and non-compaction cardiomyopathy (mainly pos-
teriorly in the left ventricle), also vacuolization of the cytoplasma was
seen (a finding consistent with Danon’s disease). The patient was sub-
sequently seen by the neurologist, but no myopathy was found. The
ophthalmologist documented Danon disease-associated eye disease
in her left eye. At the last follow-up (September 2018), Case 1 was
clinically stable in New York Heart Association Class I.
Case 2
Case 2 was 25 years of age when a LAMP-2 mutation was found. Her
medical history revealed incessant complex ventricular tachycardias
since early childhood. Around the age of 14, she underwent a cardiac
electrophysiologic study, because she had developed atrial tachycar-
dias. The electrogram showed signs of pre-excitation (Figure 1B) with
a positive deltawave in the inferior leads and negative T waves in the
anterior leads. The diagnostic electrophysiologic study identified a
fasciculoventricular connection, but no ablation was performed be-
cause no sustained tachycardias could be induced during the study. In
the years, thereafter, the patient was administered several antiar-
rhythmic drugs (propafenon, sotalol) for the treatment of ventricular
tachyarrhythmias, which had variable effects. She became pregnant at
the age of 24 and her left ventricular ejection fraction, which had
been normal before pregnancy, reduced to 38%. Cardiovascular mag-
netic resonance imaging revealed multiple areas of late enhancement.
After the pregnancy, angiotensin-converting enzyme inhibitor and
diuretics were started and amiodarone was introduced to suppress
the ventricular tachycardias. An internal cardioverter defibrillator
(ICD) was also implanted (Class IIa indication) as primary prevention.
Her left ventricular ejection fraction then increased, going up to 48%.
In the 4 years of follow-up after ICD implantation, she underwent
electrical cardioversion twice because of atrial fibrillation. Genetic
evaluation was proposed, and a frameshift mutation found in LAMP2
(c.966dup p.(Ala323Cysfs*27) (NM_002294.2)). Neurological evalu-
ation was within normal limits, but signs of retinopathy were found
by the ophthalmologist. At the last follow-up (September 2018), she
was clinically stable in New York Heart Association Class I.
Case 3
Case 3 was referred in August 2017 at the age of 20 years with recur-
rent near syncope. This was a complaint, she had been having since
Case 1 June 2011 Admission for acute heart failure. Short PR
interval without pre-excitation and broad-
ened and fractioned QRS complexes.




Admission for cardiac shock. Mechanical
support with biventricular Centrimag.
Heart transplantation.








Many antiarrhythmic drugs tried in the fol-
lowing years.
June 2013 Pregnancy, left ventricular ejection fraction
dropped to 38%. Cardiovascular magnet-
ic resonance imaging showed dilated
cardiomyopathy.
August 2014 LAMP-2 mutation found.
Case 3 August 2017 Referral for recurrent near syncope.
Electrocardiogram showed short PR
interval. Accessory pathway identified by
EP study was ablated.
October 2017 LAMP-2 mutation found.
August 2018 Implantable cardioverter defibrillator
implantation.
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Figure 1 (A) An electrocardiogram of Case 1 showing sinus tachycardia, a short PR interval without pre-excitation and broadened and fractioned
QRS complexes with inferolateral repolarization abnormalities. (B) An electrocardiogram of Case 2 showing with signs of pre-excitation with a posi-
tive deltawave in the inferior leads and negative T waves in the anterior leads. (C) Electrocardiogram of Case 3 with a short PR interval and pro-
nounced left ventricular hypertrophy with deep negative T waves is shown.


































































































puberty, but it had been occurring much more frequently in the
months leading up to her referral. The patient had never lost con-
sciousness or felt palpitations. She had been feeling fatigued for years
but had not noticed a decline in exercise tolerance.
Echocardiography showed massive LVH with speckles in the myocar-
dium and good contractility (calculated indexed mass 237.3 g/m2,
maximum septal thickness 18 mm). Cardiovascular magnetic reson-
ance imaging revealed concentric LVH with extensive diffuse mid-
myocardial-delayed enhancement (calculated myocardial mass 154 g/
m2) (Figure 3). In systole, there was apical and mid-cavitary obliter-
ation of the left ventricle with a maximum velocity of 2.3 m/s and
without left ventricular outflow tract obstruction. Ambulatory moni-
toring registered frequent supraventricular tachycardia. She was
therefore referred for ablation. Her ECG (Figure 1C) showed a short
PR interval and pronounced LVH with deep negative T waves. A car-
diac electrophysiologic study showed a single accessory pathway
with only retrograde conduction properties. Orthodromic circus
movement tachycardia was induced (non-sustained). The pathway,
which was located infero-anteriorly, was successfully ablated. Since
there was no antegrade-conducting accessory pathway, the short PR
interval could not be explained by pre-excitation, so it was most like-
ly due to enhanced AV nodal conduction. In October 2017, DNA
testing identified a de novo frameshift mutation in the LAMP2 gene
(c.929-1G>A). Interestingly, retinal pigment changes had been
observed in the patient in early 2000. In 2012, she was diagnosed
with a form of ocular albinism but had no complaints about her eye-
sight. Ophthalmologic re-examination in 2017 showed bilateral ret-
inal pigment changes associated with Danon disease. Since Danon
disease has been suggested to have a more progressive clinical course
with respect to ventricular arrhythmias and development of heart
failure, implantation of an ICD was discussed and an ICD implanted in
August 2018. Neurological examination showed no signs of myop-
athy. At the time of writing (August 2018), she is clinically stable.
Genetic testing/mutations
Targeted sequencing, data analysis and
interpretation
Genomic DNA was extracted from peripheral blood. Sample prepar-
ation and targeted enrichment were performed according to the
manufacturer’s instructions (SureSelect XT Custom library and prep
kit, Agilent Technologies Inc., Santa Clara, CA, USA) as described
previously.4 Capture probes for cardiomyopathy-related genes were
used. Enriched DNA fragments were sequenced on a MiSeq sequen-
cer (Illumina, San Diego, CA, USA) using 151 bp paired-end reads
according to manufacturer’s instructions. Data analysis was per-
formed using the MiSeq reporter programme to generate fastq.gz
output files. These were uploaded to the NextGene software (v2.2.1,
Softgenetics, State College, PA, USA) and, upon quality filtering,
aligned to the reference genome (Human_v37.2). Single-nucleotide
polymorphisms (SNPs) and indels were called, and the respective
variant list was converted into the *.vcf file format. These files were
uploaded into the Cartagenia software (Cartagenia, Leuven,
Belgium). This software was used in combination with the Alamut
software (Interactive Biosoftware, Rouen, France) for variant filtering
and classification.
CNV analysis (SNP array)
To identify putative copy number variations (CNVs) in Case 1,
genome-wide genotyping was performed using HumanCytoSNP-
850K SNP array according to the manufacturer’s protocols
(Illumina). Raw data were normalized and converted into genotypes
using the GenomeStudio data analysis software and NEXUS
(BioDiscovery). CNVs were predefined as the loss of regions of
DNA >150 kbp or of at least one exon of a gene associated with dis-
ease in OMIM (http://ncbi.nlm.nih.gov/omim) or the gain of regions of
DNA >200 kbp in size.
Genetic testing in Cases 1, 2, and 3
Case 1 was referred for genetic testing at 20 years of age. The family
history was negative for cardiac disorders. Sanger sequencing of the
genes MYH7, MYBPC3, TNNT2, TNNI3, LMNA, and PLN showed
no abnormalities. Five years later, the patient was referred for further
genetic testing after she was informed about new genetic diagnostic
possibilities. Targeted sequencing of 60 cardiomyopathy related
genes identified a de novo splice mutation, c.557-1G>C, in the LAMP2
gene. The other 59 genes showed no additional relevant mutations/-
variants. Because the patient had a slight learning disability, a SNP
array was also performed and showed a normal female pattern.
Case 2 was referred for genetic testing at 25 years of age. The fam-
ily history was negative for cardiac disorders. Targeted sequencing of
53 cardiomyopathy-related genes identified a frameshift mutation,
c.966dup p.(Ala323Cysfs*27), in the LAMP2 gene. No additional rele-
vant mutations/variants were identified in the other 52 genes.
Case 3 was referred for genetic testing at 20 years of age.
The family history was unremarkable for cardiac disorders.
Targeted sequencing of 64 cardiomyopathy-related genes identi-
fied a de novo frameshift mutation, c.929-1G>A, in the LAMP2
gene. The other 63 genes showed no additional relevant muta-
tions/variants.
Figure 2 A cardiovascular magnetic resonance imaging of Case 2
without signs of non-compaction cardiomyopathy.




















We report three female patients presenting with unexplained cardiac
disease who were eventually diagnosed with Danon disease. All three
had a history of cardiac symptoms due to heart failure (Case 1), com-
plex arrhythmias (Case 2), and near syncope (Case 3). All three were
not diagnosed until a LAMP2 mutation was found. None had neuro-
logical symptoms. On ophthalmologic examination, all three had ret-
inal pigment changes consistent with Danon disease, and Case 3 had
also been diagnosed previously with a type of ocular albinism.
Danon disease is rare in males but is even rarer in females.
Moreover, the classic Danon disease triad of clinical characteristics
Figure 3 An echocardiogram (A) and cardiovascular magnetic resonance imaging (B) of Case 3 with concentric left ventricular hypertrophy.























(proximal myopathy, mental retardation, and hypertrophic cardiomy-
opathy) is often not present in female patients (Figure 4).2 An import-
ant diagnostic clue in these female cases is the presence of a kind of
‘pre-excitation’ (as we saw in Cases 1 and 3).5,6 Historically, Danon
disease has been associated with hypertrophic cardiomyopathy.1
However, some female patients present with a dilated cardiomyop-
athy phenotype during or after delivery of a child, as we saw in Case
2, which could suggest that some cases of peri-partum cardiomyop-
athy are due to LAMP2 mutations.7,8 Indeed, an equal percentage of
dilated and hypertrophic cardiomyopathy cases can be expected in
female patients.9 In addition, our Case 2 had no clear signs of pre-
excitation even through this is a finding commonly described in
patients with Danon.8
Several other differences can be found between males and females
with Danon disease. Males more often report cognitive and skeletal
muscle complaints, although recent data suggests that females have
these complaints more often than previously recognized.9 The mean
age of first symptoms is also later in females (27.9 years vs. 12.1 years
in males), as is the time to first heart transplantation, and survival is
longer in female patients.9,10 However, a study in a family with many
female carriers showed that the symptoms of heart failure can be rap-
idly progressive, and early heart transplantation should therefore be
considered in these patients.6 As Case 2 illustrated, mechanical sup-
port is sometimes needed, as bridge to decision, and there are also
reports with permanent left ventricular assist devices.11,12
Additionally, the incidence of sudden death was reported to be high
in this family, with four of six females dying suddenly between 37 and
54 years of age.6 Therefore, given the variability of presentation, clin-
ical diagnosis of Danon disease in women can be very challenging,
which emphasizes the importance of genetic testing to look for
LAMP2 mutations.
In conclusion, Danon disease is a rare disease in which the primar-
ily cardiac phenotype seen in our three female cases is even rarer.
These cases show that presentation in women can be more variable
than that typically seen in men. One should, therefore, consider
Danon disease in female patients with either heart failure or
arrhythmias without a clear diagnosis and/or with a pre-excitation-
like ECG, and genetic testing plays a crucial role in this diagnosis.
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Figure 4 The left side shows the classical triad of Danon’s disease in male patients. On the right side, a chronological series of events is shown for
the female patients in the present case series. It starts with unexplained left ventricular hypertrophy and ends with a final diagnosis by genetic testing.
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